OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of “Hold” by Brokerages

Shares of OPKO Health, Inc. (NASDAQ:OPK) have earned a consensus recommendation of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $1.55.

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. HC Wainwright restated a “buy” rating on shares of OPKO Health in a report on Wednesday, July 29th. Finally, Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.64 on Tuesday. The firm has a market capitalization of $1.22 billion, a P/E ratio of -18.22 and a beta of 1.50. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.73. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93. The business’s 50-day simple moving average is $1.40 and its 200-day simple moving average is $1.30.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.07. The business had revenue of $163.58 million during the quarter, compared to analysts’ expectations of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.19) EPS. Equities analysts predict that OPKO Health will post -0.23 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in OPKO Health during the 2nd quarter worth approximately $55,468,000. Geode Capital Management LLC boosted its stake in shares of OPKO Health by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock valued at $13,940,000 after buying an additional 67,973 shares during the last quarter. Millennium Management LLC grew its position in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after buying an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after buying an additional 3,600,378 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of OPKO Health by 12.1% in the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 577,248 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.